

REVIEW

Open Access



Update on the genetic and epigenetic etiology of gestational diabetes mellitus: a review

Tajudeen O. Yahaya^{1*}, Titilola Salisu², Yusuf B. Abdulrahman³ and Abdulrazak K. Umar³

Abstract

Background: Many studies have been conducted on the genetic and epigenetic etiology of gestational diabetes mellitus (GDM) in the last two decades because of the disease's increasing prevalence and role in global diabetes mellitus (DM) explosion. An update on the genetic and epigenetic etiology of GDM then becomes imperative to better understand and stem the rising incidence of the disease. This review, therefore, articulated GDM candidate genes and their pathophysiology for the awareness of stakeholders.

Main body (genetic and epigenetic etiology, GDM): The search discovered 83 GDM candidate genes, of which *TCF7L2*, *MTNR1B*, *CDKAL1*, *IRS1*, and *KCNQ1* are the most prevalent. Certain polymorphisms of these genes can modulate beta-cell dysfunction, adiposity, obesity, and insulin resistance through several mechanisms. Environmental triggers such as diets, pollutants, and microbes may also cause epigenetic changes in these genes, resulting in a loss of insulin-boosting and glucose metabolism functions. Early detection and adequate management may resolve the condition after delivery; otherwise, it will progress to maternal type 2 diabetes mellitus (T2DM) and fetal configuration to future obesity and DM. This shows that GDM is a strong risk factor for T2DM and, in rare cases, type 1 diabetes mellitus (T1DM) and maturity-onset diabetes of the young (MODY). This further shows that GDM significantly contributes to the rising incidence and burden of DM worldwide and its prevention may reverse the trend.

Conclusion: Mutations and epigenetic changes in certain genes are strong risk factors for GDM. For affected individuals with such etiologies, medical practitioners should formulate drugs and treatment procedures that target these genes and their pathophysiology.

Keywords: Adiposity, Beta-cell dysfunction, Epigenetics, Insulin resistance, Obesity

Background

Pregnant women develop insulin resistance at certain stages owing to increased placenta hormones, but most women overcome this condition by up-regulating insulin production through beta cell expansion [1]. Gestational diabetes mellitus (GDM) begins when a pregnant female does not make the extra insulin needed to normalize blood glucose during the second or third trimester of pregnancy [1]. Sometimes the glucose intolerance may be present before pregnancy, but not diagnosed [2, 3]. Uncontrolled GDM can cause high blood pressure, type

2 diabetes mellitus (T2DM), and increased risks of vascular diseases in pregnant women [4, 5]. Intrauterine exposure to high blood glucose may program the offspring to develop diabetes or obesity later in life [6]. It may also cause macrosomia, birth defects, preterm birth, and developmental delay [7–9].

GDM is the most common metabolic condition during pregnancy [10] with a global incidence rate between 1 and 28 % [11]. In 2017, GDM affected about 204 million women worldwide with a projection to increase to 308 million by 2045, mostly in developing countries [12]. Though most times the glucose intolerance normalizes soon after delivery, women with GDM have a high risk of developing T2DM later in life [13]. Compared to women with normal glucose tolerance, women with

* Correspondence: yahayatajudeen@gmail.com; yahaya.tajudeen@fubk.edu.ng

¹Federal University Birnin Kebbi, PMB 1157 Birnin Kebbi, Nigeria
Full list of author information is available at the end of the article

GDM are at least seven times more predisposed to T2DM [14]. Moreover, almost half of pregnant females with GDM will develop diabetes in a decade [14]. Offspring of women with GDM are also 8 times more prone to diabetes or pre-diabetes [15]. These show that GDM contributes immensely to the alarming incidence of diabetes worldwide [16]. Diabetes affected about 451 million people in 2017, of which 5 million died and USD 850 billion was spent on healthcare expenditure [17]. Considering the impact of GDM, the reduction of its prevalence and effective management of the affected will go a long way in stemming the incidence and burden of diabetes. However, to achieve a reduced prevalence of GDM, a proper understanding of its etiology is necessary. Fortunately, improved biological techniques in the last two decades have led to more understanding of the genetic and epigenetic etiology of the disease, thus an update becomes necessary. This review therefore articulated current findings on the genetic and epigenetic etiology of GDM.

Methods

Databases searched

An in-depth search of PubMed, Scopus, SpringerLink, Google Scholar, and ResearchGate databases was performed for relevant research articles on GDM.

Search terms

Some search terms used to retrieve articles are gestational diabetes mellitus, hyperglycemia, insulin resistance, obesity, glucose metabolism, beta-cell dysfunction, and gestational diabetes genes. Other search terms used include glucose insensitivity, epigenetics of diabetes mellitus, gestational diabetes testing and cost-effectiveness, and the prevalence of gestational diabetes.

Article inclusion criteria

Inclusion criteria include the following:

- Research published in the English language.
- Research that focused on GDM.
- Studies that focused on the genetic and epigenetic etiology of GDM.
- Articles that centered on GDM testing and cost-effectiveness.
- Studies published between 2000 till date.

Article exclusion criteria

Exclusion criteria include the following:

- Studies that are not available in English language.
- Studies with only abstract available.
- Research that described GDM, but with no clear genetic and epigenetic mechanisms
- Studies published before the year 2000.

Results

Genetic etiology in GDM

The search found that mutations in some genes, or their variants, may interact with one another and environmental triggers to cause GDM (Fig. 1). The genetic etiology of GDM overlaps with T2DM, as most of the GDM candidate genes also predispose humans to T2DM. This explains the common pathophysiology of GDM and T2DM as both express beta-cell dysfunction and abnormal glucose metabolism [18]. Contrary to some reports, GDM also shares common pathophysiology with type 1 diabetes mellitus (T1DM) and maturity-onset diabetes of the young (MODY), but less than 10 % of GDM patients show these associations [18].

Though many genes reportedly showed an association with obesity, insulin resistance, and beta-cell dysfunction, the present study discovered only 83 genes with a clear GDM pathophysiology and are presented in Table 1.


Most frequent GDM candidate genes

The list of GDM candidate genes is inexhaustible as more genes are continually discovered; however, certain genes are most often linked with the disease. Table 2 shows the most frequent GDM candidate genes and their variants in various ethnic groups.

From Table 2, we used a pie chart (Fig. 2) to express the percentage occurrence of each gene based on ethnicity. *TCF7L2* gene was the most frequent having present in 17 % of the ethnics, followed by *MTNR1B* with 15 %, *CDKAL1* 10 %, *KCNQ1* 10 %, and *IRS1* 10 %. Some other genes are not widespread, but are often found in certain ethnics or regions. These genes include *ZRANB3*, found in Africa [96]; *ABCC8* found among Finnish [119]; *Chemerin*, found among Iranians [120]; and *INS*, found among the Greeks [121]. These genes can be used to develop a genetic testing guideline to predict the likelihood of GDM or determine its genetic and epigenetic etiology. This is important because there is no genetic testing procedure yet for GDM, partly because the condition is multifactorial in which several genes interact with environmental triggers to cause the disease. Thus, a mutation in a single gene may not explain full susceptibility to GDM and testing for all the candidate genes will be expensive and cumbersome. The low prevalence of GDM in the past also contributes to the lack of interest in developing a genetic testing guideline for the disease.

Epigenetic etiology in GDM

Epigenetics refers to the study of heritable changes in biological processes caused by modification of chemical tags on DNA such as methyl and ethyl groups [122]. These modifications are mediated by some mechanisms, including DNA methylation, histone modification, and



microRNA expression [122]. Epigenetic mechanisms play important roles in several cellular activities, but certain environmental triggers can reprogram the epigenome, resulting in disease pathologies [123]. In particular, epigenetic mechanisms regulate several genes that maintain beta-cell morphology, proliferation, and functions, thus implies that epigenetic modification may disrupt insulin secretion and sensitivity, causing metabolic diseases, including GDM [124, 125]. Epigenetic changes are expressed in both somatic and gamete cells, and thus can be transmitted from generation to generation [126].

Studies have reported many instances of epigenetic modifications involving insulin synthesis and glucose metabolism in GDM. For instance, histone under-acetylation and over-methylation in the promoter region of the *PDX1* gene reduce the insulin-boosting function of the gene [127]. Also, in a study that examined the methylation of the *IL-10* gene among pregnant women, hypo-methylation of maternal blood cells and elevated plasma *IL-10* levels were noticed in women with GDM [128]. In another study that compared the *miRNA* profiles of some diabetic pregnant rats with nondiabetic, repression of *miR-338* and overexpression of *miR-451* were associated with reduced β -cell mass in the diabetic [129]. In vitro upregulation of *miR-451* and repression of *miR-338* in the same study increased β -cell mass, leading to improved glucose metabolism [129]. In a study that investigated the *miRNA* expressions of maternal and fetal blood cells of some pregnant women, 29 *miRNAs* were upregulated in individuals with GDM [130]. Of these *miRNAs*, *miRNA-340* was confirmed to downregulate the expression of the *PAIP1* gene [130]. In vitro normalization of the *miRNA-340* expression of the diabetic mothers increased insulin production [130].

Environmental triggers of genetic and epigenetic etiology of GDM

Both the genetic and epigenetic etiology of GDM are mediated by certain environmental triggers that change gene functions. The genetic triggers mutate the genes, while the epigenetic triggers affect the chemical tags on the DNA without affecting the nucleotide sequence (Fig. 3). Among the environmental triggers are pollution and microbial exposures, whose GDM modulatory roles have been established by several studies. In a study that monitored the effects of air pollution among pregnant Southern Californians, prepregnancy exposures to nitrogen dioxide (NO_2), particulate matter ($\text{PM}_{2.5}$ and PM_{10}), and dioxin were related to GDM [131]. Nitrogen dioxide and particulate matter can cause oxidative stress, overexpression of proinflammatory cytokines, and endothelial dysfunction, resulting in increased insulin resistance [132]. Dioxin compounds can interact with peroxisome proliferator-activated receptor- γ (*PPARG*), disrupting insulin signaling pathways and resulting in insulin resistance and abnormal glucose metabolism [133]. Exposure to pathogenic microbial organisms may disrupt the gut microbiota and compromise the immune system, leading to metabolic disorders and GDM. Vu *et al.* [134] demonstrated in rabbits that a toxin produced by *Staphylococcus aureus* may interact with fat cells and the immune system, resulting in inflammation, insulin resistance and glucose intolerance [134]. In a study of the microbiota of some pregnant women, individuals with GDM showed gut microbiota imbalance containing majorly the phylum Actinobacteria and the genus *Collinsella*, *Rothia* and *Desulfovibrio* [135]. A balanced gut microbiota is necessary for optimum metabolism and the immune system. Aside from microbial infection, other environmental factors that may disrupt

Table 1 GDM predisposing genes showing locations and pathophysiology

Number	Gene	Full name	Locus	Pathophysiology
1	<i>TCF7L2</i>	Transcription factor 7-like 2	10q2	Increases apoptosis, impairing insulin secretion [19].
2	<i>KCNQ1</i>	Potassium voltage-gated channel sub-family Q member 1	11p15.5-15.4	It disrupts the influx of calcium into the channel, resulting in decreased insulin secretion [20].
3	<i>CENTD2/ARAP1</i>	Centaurin-delta-2/ ArfGAP with rhoGAP domain, ankyrin repeat and PH domain 1	11q13.4	Causes disruption of glucose-induced insulin secretion [21].
4	<i>MTNR1B</i>	Melatonin receptor 1B	11q14.3	Decreases insulin secretion, elevating fasting glucose levels [22].
5	<i>IGF1</i>	Insulin-like growth factor 1	12q23.2	Induces high body mass (HBM), leading to metabolic disturbances, especially insulin resistance and hyperinsulinemia [23].
6	<i>IGF2</i>	Insulin-like growth factor 2	11p15.5	Overexpression of IGF2 leads to β -cell dedifferentiation and endoplasmic reticulum stress, causing islet dysfunction [24].
7	<i>IGFBP-1</i>	Insulin like growth factor binding protein 1	7p12.3	Decreased blood levels of IGFBP-1 cause overexpression of IGF-I, resulting in inflammation [25].
8	<i>IGFBP-2</i>	Insulin like growth factor binding protein 3	2q35	Reduced expression of IGFBP-2 inhibits adipogenesis, leading to obesity and insulin resistance [26].
9	<i>IGF2BP2</i>	Insulin like growth factor 2 mRNA binding protein 2	3q27.2	Impairs β -cell function and modulates obesity, altering insulin sensitivity [27].
10	<i>IGFBP-3</i>	Insulin like growth factor binding protein 3	7p12.3	Overexpression of IGFBP-3 predisposes to HBM body, disrupting glucose metabolism [28].
11	<i>IGFBP-4</i>	Insulin like growth factor binding protein 4	17q21.2	Reduced levels cause HBM and insulin resistance [28].
12	<i>IGFBP5</i>	Insulin like growth factor binding protein 5	2q35	Disrupts IGF-1 signaling pathway, leading to insulin insensitivity [29].
13	<i>PPARG</i>	Peroxisome proliferator-activated receptor gamma	3p25.2	Stimulates abnormal fat deposition in tissues, causing obesity and insulin resistance [27].
14	<i>KCNJ11</i>	Potassium voltage-gated channel sub-family J member 11	11p15.1	Reduces the sensitivity of pancreatic beta-cell KATP channel subunit (Kir6.2), resulting in decreased insulin release [28].
15	<i>INSR</i>	Insulin receptor	19p13.2	Predisposes to obesity, leading to insulin resistance [29].
16	<i>ADRB2</i>	Adrenoceptor beta 2	5q32	Increases the secretion of vascular endothelial growth Factor-A (VEGF-A) in the β -cells, resulting in hyper-vascularized islets and disrupting insulin secretion and glucose metabolism [30].
17	<i>ADRB3</i>	Adrenoceptor beta 3	8p11.23	Increases body weight, predisposing to obesity and insulin resistance [31].
18	<i>GNB3</i>	G protein subunit beta 3	12p13.31	Causes high-fat deposition and obesity [32].
19	<i>ABCC8</i>	ATP binding cassette subfamily c member 8	11p15.1	Loss of function of the gene disrupts the KATP channel function, increasing the body weight and causing hyperinsulinism [33].
20	<i>CAPN10</i>	Malpain 10	2q37.3	Increases body mass, initiating insulin resistance [34].
21	<i>MBL2</i>	Mannose-binding lectin	10q21.1	Causes frequent infections and chronic inflammatory diseases, leading to high-fat deposition and insulin resistance [35].
22	<i>GLUT4/SLC2A4</i>	Glucose transporter type 4/Solute carrier family 2 member 4	17p13.1	Impairs insulin signaling pathway [36].
23	<i>RBP4</i>	Retinol binding protein-4	10q23.33	Increases gluconeogenesis and impairs insulin signaling in muscles [37].
24	<i>PCK1</i>	Phosphoenolpyruvate carboxykinase 1	20q13.31	Induces high levels of fasting insulin, causing abnormal glucose metabolism [38].
25	<i>PIK3R1/PI3K</i>	Phosphoinositide-3-kinase regulatory subunit 1	5q13.1	Disrupts insulin signaling pathway in skeletal muscle and inhibit liver gluconeogenesis [38].
26	<i>STRA6</i>	Signaling receptor and transporter of retinol STRA6	15q24.1	Promotes fat deposition, predisposing to obesity and insulin resistance [39].
27	<i>VDR</i>	Vitamin D receptor	12q13	Predisposes to obesity, causing metabolic disorder, especially insulin resistance [40, 41].
28	<i>CDKAL1</i>	Cyclin-dependent Kinase 5 Regulatory subunit-associated protein 1-like 1	6p22.3	Inhibits the conversion of proinsulin to insulin through protein translation, leading to insulin resistance [42].
29	<i>GCK</i>	Glucokinase	7p13	Increases body fat mass, resulting in insulin resistance [43].

Table 1 GDM predisposing genes showing locations and pathophysiology (*Continued*)

Number	Gene	Full name	Locus	Pathophysiology
30	<i>CDKN2A/2B</i>	Cyclin-dependent kinase inhibitor 2a	9p21.3	Affects proinsulin conversion to insulin and reduces insulin sensitivity [44].
31	<i>SRR</i>	Serine racemase	17p13.3	Disrupts the secretion of insulin and/or glucagon [45].
32	<i>HHEX/IDE</i>	Hematopoietically expressed homeobox	10q23.33	Causes pancreatic and liver developmental error [46].
33	<i>SLC30A8</i>	Solute carrier family 30 member 8	8q24.11	Modulates loss of zinc in the beta cells, destabilizing insulin molecules [47].
34	<i>LEP</i>	Leptin	7q31.3	Promotes inflammation, causing energy imbalance and obesity [48].
35	<i>LEPR</i>	leptin receptor	1p31	Induces high-fat mass and insulin resistance [49].
36	<i>HNF1B/TCF2</i>	Hepatocyte nuclear factor 1B	17q12	Causes β -cell dysfunction [50, 51].
37	<i>TNF-α/TNF</i>	Tumor necrosis factor- α	6p21.33	Causes inflammatory and oxidative stress [52].
38	<i>HNF4A/TCF1</i>	Hepatocyte nuclear factor 4 alpha	20q12	Induces β -cell dysfunction [50, 51].
39	<i>WFS1</i>	Wolfram syndrome 1	4p16.1	Initiates endoplasmic reticulum stress and mitochondrial disorder, leading to β -cell dysfunction [53].
40	<i>IRS1</i>	insulin receptor substrate 1	2q36.3	Induces an inflammatory response and causing low insulin sensitivity [54].
41	<i>HTR2B/ 5-HT-1A</i>	5-hydroxytryptamine receptor 1a	5q12.3	Reduces beta-cell proliferation and increases body weight [55].
42	<i>TPH1</i>	Tryptophan hydroxylase 1	11p15.1	Causes low levels of serotonin, increasing weight gain and causing insulin intolerance [56].
43	<i>5-HT1A/ HTR3A</i>	5-hydroxytryptamine receptor 1a	5q12.3	Causes low serotonin levels, resulting in insulin resistance [57].
44	<i>HNF1A</i>	Hepatocyte nuclear factor-1 alpha	12q24.31	Causes adiposity, leading to pre-pregnancy obesity and insulin resistance [57].
45	<i>GCKR</i>	Glucokinase regulator	2p23.3	Overexpression of GCKR causes hyperactivity of GCK, reducing glucose and increasing fat accumulation [58]. Loss of the function reduces GCK expression, impairing glucose clearance [59].
46	<i>MIF</i>	Macrophage migration inhibitory factor	22q11.23	Overexpression of the MIF gene in placental tissue causes insulin resistance [60].
47	<i>ADRA2A</i>	Alpha-2-adrenergic receptors	10q25.2	Increases body fat mass, leading to loss of glucose regulation [61].
48	<i>SLC6A4</i>	Solute carrier family 6 member 4	17q11.2	Impairs serotonin metabolism, increasing body weight and causing insulin resistance [62].
49	<i>FTO</i>	Fat mass and obesity-associated gene/ Alpha-ketoglutarate dependent dioxygenase	16q12.2	Causes adiposity, leading to pre-pregnancy obesity and insulin resistance [63].
50	<i>TLE1</i>	Transducin-like enhancer of split-1	9q21.32	Elevates fasting glucose level and reduces insulin secretion [64].
51	<i>ADCY5</i>	Adenylate cyclase 5	3q21.1	Alters ADCY5 expression in pancreatic beta cells, impairing glucose signaling [65].
52	<i>IL-1β</i>	Interleukin-1 beta	2q14.1	Impairs pancreatic β -cells, decreasing insulin secretion [66].
53	<i>IL-6</i>	Interleukin-6	7p15.3	Overexpression destroys pancreatic β -cells, resulting in apoptosis and low insulin synthesis [67].
54	<i>IL-10</i>	Interleukin-10	1q32.1	Overexpression compromises immune response, disrupting insulin metabolism [68].
55	<i>PAX8</i>	Paired box 8	2q14.1	Reduces islet viability and beta cell survival [69].
56	<i>ADIPOQ (diponectin gene)</i>	Adiponectin, C1Q and collagen domain containing	3q27.3	Causes low adiponectin, leading to obesity and insulin resistance [70].
57	<i>RARRES2 (Chemerin gene)</i>	retinoic acid receptor responder 2	7q36.1	Initiates inflammation and energy imbalance, leading to obesity and insulin resistance [71].
58	<i>SERPINA12 (Vaspin gene)</i>	Serpin family a member 12	14q32.13	Causes inflammation, loss of energy balance, and obesity [72].
59	<i>RETN</i>	Resistin	19p13.2	Causes a loss of energy balance, obesity, and insulin resistance [73].

Table 1 GDM predisposing genes showing locations and pathophysiology (*Continued*)

Number	Gene	Full name	Locus	Pathophysiology
60	<i>APLN</i>	Apelin	Xq26.1	Causes a loss of energy balance, obesity, and insulin resistance [74].
61	<i>NUCB2</i> (<i>nesfatin 1</i> gene)	Nucleobindin 2	11p15.1	Causes a loss of energy balance, obesity, and insulin resistance [75].
62	<i>ITLN1</i>	Intelectin-1/Omentin-1	1q23.3	Loss of function induces insulin resistance [76].
63	<i>NAMPT/PBEF1</i> (<i>Visfatin</i> gene)	Nicotinamide phosphoribosyltransferase	7q22.3	Causes obesity and insulin resistance [76].
64	<i>HMG20A/</i> <i>iBRAf</i>	High mobility group protein 20a	15q24.3	Depletion represses expression of insulin-producing genes such as NeuroD, Mafa and GCK, and enhances beta-cell de-differentiating gene such as PAX4 and REST [77].
65	<i>RREB1</i>	Ras responsive element binding protein 1	6p24.3	Causes fat deposition and beta cell dysfunction [78].
66	<i>GLIS3</i>	GLIS family zinc finger 3	9p24.2	Causes fat deposition and beta cell dysfunction [78].
67	<i>GPSM1</i>	G protein signaling modulator 1	9q34.3	Causes fat deposition and beta cell dysfunction [78].
68	<i>mtDNA</i>	Mitochondrial DNA	All cells	Induces oxidative stress and mitochondrial disorder, causing insulin resistance [79].
69	<i>PRLR</i>	Prolactin receptor	5p13.2	Modulates loss of PRLR signaling in β -cells. reducing β -cell proliferation and expansion during pregnancy [80].
70	<i>MAFB</i>	MAF bZIP transcription factor B	20q12	Causes inadequate β -cell expansion [80].
71	<i>SERT</i>	Serotonin transporter	17q11.1-12	Stimulates abnormal fat accumulation in both white and brown adipose tissues, causing glucose intolerance and insulin resistance [81].
72	<i>PAI-1</i>	Plasminogen activator inhibitor 1	7q22	Predisposes to adiposity, increasing body weight and affecting pancreatic beta-cell function [82].
73	<i>TSPAN8</i>	Tetraspanin-8	12q21.1	Impairs gestational glucose tolerance [83].
74	<i>G6PC2</i>	Glucose-6-phosphatase catalytic subunit 2	2q31.1	Elevates fasting glucose level and reduces insulin secretion [64].
75	<i>PTPRD</i>	Protein tyrosine phosphatase receptor type d	9p24.1-p23	Disrupts insulin signaling pathway, leading to altered insulin sensitivity and glucose homeostasis [84].
76	<i>CRP</i>	C-reactive protein	1q23.2	Overexpression causes obesity, resulting in systemic inflammation and insulin resistance [85].
77	<i>GK</i>	Glycerol kinase	Xp21.2	Deficiency causes abnormal insulin metabolism [86].
78	<i>PAX4</i>	Paired box gene 4	7q32.1	Impairs fetal islet cell differentiation, altering insulin sensitivity later in life [87].
79	<i>HDAC4</i>	Histone deacetylase 4	2q37.3	Causes β -cell loss, leading to decreased insulin secretion. Also represses beta-cell transcriptional factors [88].
80	<i>FETUA/ AHSG</i>	Fetuin-a	3q27.3	Increases body mass, insulin secretion and C-peptide levels, but lower insulin sensitivity [89].
81	<i>FETUB</i>	Fetuin-b	3q27.3	Increases hepatic steatosis, impairing insulin secretion and glucose metabolism [90].
82	<i>FGF21</i>	Fibroblast growth factor 21	10q26.13	Cause an abnormal glucose metabolism independent of insulin resistance [91].
83	<i>SNORA8</i>			An emerging candidate gene [92]

gut microbiota include certain diseases, oral microbiome, diets, and antibiotic use, among others [136].

Lifestyles such as short sleep, poor nutritional choices, advanced age, and physical inactivity are some environmental triggers that may predispose humans to GDM. Short hour sleep at night can increase body fat accumulation, reduce glucose metabolism, and predispose to T2DM and GDM. In a study that determines the frequency of GDM

among sleep-deprived 668 Singaporeans, 131, representing 19 %, were diagnosed with GDM of which 27.3 % sleep less than 6 hours a night, while 16.8 % sleep between 7-8 hours [137]. Poor nutrition, such as energy-dense western diets may cause overweight and obesity, disrupting insulin signaling pathways and insulin sensitivity. Saturated fats can disrupt insulin signaling, induce inflammation and endothelial dysfunction, resulting in GDM. In a study that evaluated

Table 2 Most prevalent gestational diabetes mellitus genes across countries, ethnicity, and race in the world

Gene	Countries/ethnicity/race	Variants	Level of significance	References	
<i>TCF7L2</i>	Mexicans	rs7901695	$P = 2.16 \times 10^{-6}$	[93]	
		rs7901696	$P < 0.05$	[93]	
		rs7901697	$P < 0.05$	[93]	
		rs7901698	$P < 0.05$	[93]	
		Asians	rs7903146	$P = 0.001$	[94]
		Scandinavians	rs7903146	$P < 0.05$	[95]
		Africans	rs7903146	$P = 7.288 \times 10^{-13}$	[96]
		Hispanic/Latinos	rs7903146	$P < 0.05$	[97]
	Caucasians/Danish	rs7903146	$P = 0.00017$	[98]	
	Caucasian	rs4506565	$P < 0.001$	[99]	
<i>KCNQ1</i>	Mexicans	rs2237892	$P = 1.98 \times 10^{-5}$	[93]	
		rs163184	$P < 0.05$	[93]	
		rs2237897	$P < 0.05$	[93]	
	Koreans	rs2074196	$P = 0.039$	[100]	
		rs2237892	$P < 0.05$	[100]	
	East Asians	rs2074196	$P = 0.039$	[100]	
		rs2237892	$P < 0.05$	[100]	
	Pakistan	rs2237895	$P < 0.05$	[101]	
<i>MTNR1B</i>	Mexicans	rs1387153	$P = 0.05358$	[93]	
		Asians	rs10830963	$P < 0.001$	[94]
		Caucasians	rs10830963	$P < 0.001$	[94]
		Koreans	rs10830962	$P = 2.49 \times 10^{-13}$	[102]
		Danish	rs10830963	$P < 0.05$	[103]
	Saudi Arabians	rs1387153	$P < 0.05$	[103]	
		rs10830963	$P < 0.05$	[104]	
		Asians	rs1801282	$P = 0.011$	[94]
<i>PPARG</i>	Caucasians	rs1801282	$P < 0.05$	[99]	
		rs3856806	$P < 0.05$	[99]	
	Caucasians/Danish	rs1801282	$P < 0.05$	[98]	
<i>CDKAL1</i>	Koreans	rs7754840	$P = 2.49 \times 10^{-13}$	[102]	
		Caucasians	rs7756992	$P < 0.05$	[99]
	Caucasian/Danish	rs7756992	$P = 0.00017$	[98]	
	Iranians	rs7754840	$P < 0.001$	[105]	
<i>IRS1</i>	Scandinavians	IRS1 Arg972	$P < 0.05$	[106]	
	Americans	Arg972	$P < 0.05$	[107]	
	Saudi Arabians	rs1801278	$P = 0.01$	[108]	
	Austro-Hungarians	rs7578326	$P < 0.05$	[109]	
<i>HMG2</i>	Africans	rs138066904	$P = 2.516 \times 10^{-9}$	[96]	
	Africa Americans	rs343092	$P < 0.05$	[96]	
	Europeans	rs2258238	$P < 0.05$	[96]	
<i>IGF2BP2</i>	Koreans	rs4402960	$P < 0.001$	[110]	
	Caucasians/Danish	rs4402960	$P < 0.001$	[111]	
	Chinese	rs4402960	$P < 0.001$	[112]	

Table 2 Most prevalent gestational diabetes mellitus genes across countries, ethnicity, and race in the world (*Continued*)

Gene	Countries/ethnicity/race	Variants	Level of significance	References
GCKR	Malaysians	rs780094	$P < 0.05$	[113]
	American Caucasians	rs780094	$P < 0.05$	[114]
	Brazilians	rs780094	$P < 0.05$	[115]
FGF21	Iranians	Over expression of mRNA	$P < 0.001$	[116]
	Chinese	Over expression of mRNA	$P < 0.001$	[117]
	Australians	Over expression of mRNA	$P < 0.001$	[118]

the effect of dietary patterns among pregnant Chinese women, diets containing high protein and low starch were associated with a reduced risk of GDM [138]. Energy-dense diets are deficient in betaine, which is a methyl donor for methylating important biological processes and as well a substrate of methionine metabolism [139]. Diets low in betaine may induce abnormal methylation of some genes involved in insulin synthesis and glucose metabolism. Advanced age may also predispose pregnant women to GDM because mitochondrial functions decline with age, leading to reduced metabolic activities and an increased body mass index [140]. Aging changes the epigenetic pattern, affecting the expression of some genes involved in glucose metabolism, particularly the *COX7A1* gene in the respiratory chain [141]. In a study of 1688 women in northwest London who developed GDM, advanced maternal age was linked to GDM [142]. Studies that demonstrate the role of physical inactivity in the pathogenesis of GDM are scarce. However, a systematic and meta-analysis by Ming *et al.* [143] shows that physical activity during pregnancy can decrease the occurrence of GDM, suggesting that lack of exercise is a risk factor. Some mechanisms through which inactivity

mediates diseases include mitochondrial dysfunction, changes in the composition of muscles, and insulin resistance, among others [144]. Physical inactivity influences the epigenome negatively, affecting several generations [145].

GDM testing, efficacy, and cost-effectiveness

Early detection of GDM is important to prevent its short- and long-term effects, especially the maternal progression to T2DM and fetal programming to DM later in life. Certain features such as BMI above 30 kg/m² as well as previous GDM, baby birth weight of 4.5 kg or above, and macrosomia suggest a need for a GDM test [146]. Pregnant women with a family history of DM and ethnic groups with a high prevalence of DM such as Asian, Black, African-Caribbean or Middle Eastern should also consider the test [146, 147]. As stated earlier, there is no genetic testing procedure yet for GDM, however, two tests, namely glucose challenge test (GCT) and oral glucose tolerance test (OGTT) are frequently conducted at 24-28 weeks of pregnancy to diagnose GDM. The two tests can be done in succession known as 2-step screening, or OGTT alone can be done called 1-step screening.

In the 2-step screening, the GCT (otherwise known as a glucose screening test) is done first and entails testing the blood glucose one hour after drinking a sweet substance without fasting. If the blood glucose is 140 mg/dL (7.8 mmol/L) or higher, then an OGTT is necessary [148]. The OGTT measures blood glucose after 8-hour fasting, after which a glucose substance (75 g) is taken and blood glucose re-measured after 1, 2 and 3 hours. High blood glucose levels at any two or more of the blood test times suggest GDM [148]. Though the pathophysiology of GDM are similar with T2DM, a GCT of 200 mg/dL or more could indicate T2DM [148].

Relatively recently, serum levels of C-reactive protein (CRP) as well as glycated hemoglobin (HbA1c) and random blood sugar (RBS) are used as screening tools for GDM in the first trimester. CRP concentrations of about 6 mg/L or higher in undiluted serum samples are considered positive for GDM [149]. According to the International Association of the Diabetes and Pregnancy Study Group (IADPSG), the cutoff level of HbA1c is 6.5 % and RBS is 11.1 mmol (200mg/dL) [150].





Fig. 2 Percentage prevalence of most implicated GDM genes from data extracted



The cost-effectiveness of GDM testing is controversial because it depends on the region, race, screening tools, and methods. A systematic review by Fitria [151] reported that GDM testing and controlling is not effective in high-income countries. This could be due to the low prevalence of the disease in the region and the all-encompassing health care system. However, GDM testing could be worthwhile in countries with a high prevalence of GDM and nations with a poor healthcare system. For example, Marseille *et al.* [152] reported the cost-effectiveness of GDM testing using a devised model in Israel and India, which are known for high GDM incidence rates. The 2-step GTT is often recommended, however, a systematic review and meta-analysis by Saconne *et al.* [153] showed no significant cost-effective difference between the two methods. The 2-step screening is also time-consuming and inconvenient, which may put off some patients [150, 154]. Glycated hemoglobin and RBS are simple GDM screening tools and are gaining acceptance worldwide, however, more awareness and understanding of the tools are necessary.

Conclusion

Several articles reviewed showed that mutation and epigenetic modifications in certain genes can predispose humans to GDM. Most of the GDM candidate genes identified have also been implicated in the pathogenesis of T2DM, and both diseases share a common pathophysiology. The two metabolic disorders expressed oxidative stress-induced beta-cell dysfunction and insulin resistance through adiposity and obesity. One major difference between GDM and T2DM is that it resolves most times after delivery, however, it may progress to T2DM if not checked. This shows that GDM is a strong risk factor for T2DM, thus, its detection and management may reduce the prevalence of DM worldwide. Of the GDM candidate genes identified, the variants of *TCF7L2*, *MTNR1B*,

CDKAL1, *IRS1* and *KCNQ1* are the most widespread, while some others are confined to certain ethnic groups. A genetic testing procedure can be developed around these genes to predict the likelihood of GDM or determine its genetic and epigenetic etiology. This will go a long way in stemming the incidence of DM worldwide.

Abbreviations

CRP: C-reactive protein; DM: Diabetes mellitus; GCT: Glucose challenge test; GDM: Gestational diabetes mellitus; HbA1C: Glycated hemoglobin; IADPSG: International Association of the Diabetes and Pregnancy Study Group; MODY: Maturity onset diabetes of the young; NO₂: Nitrogen dioxide; OGTT: Oral glucose tolerance test; PM2.5: Particulate matter size 2.5; PM10: Particulate matter size 10; RBS: Random blood sugar; T1DM: Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus

Acknowledgements

None.

Authors' contributions

TY conceptualized, did the literature search, drafted the manuscript, and did correspondence. TS designed the article and did the literature search. YA did the article selection and proofreading. AU did the article selection and proofreading. All authors have read and approved the manuscript.

Funding

None.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Federal University Birnin Kebbi, PMB 1157 Birnin Kebbi, Nigeria. ²Department of Zoology and Environmental Biology, Olabisi Onabanjo University Ago-Iwoye, Ago-Iwoye, Ogun State, Nigeria. ³Department of Biochemistry and Molecular Biology, Federal University Birnin Kebbi, Birnin Kebbi, Nigeria.

Received: 14 November 2019 Accepted: 11 February 2020

Published online: 23 March 2020

References

- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Symptoms & Causes of Gestational Diabetes. <https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/gestational/symptoms-causes>
- Fernández-Morera JL, Rodríguez-Rodero S, Menéndez-Torre E et al (2010) The possible role of epigenetics in gestational diabetes: cause, consequence, or both. *Obstet Gynecol Int*. 2010;605163. <https://doi.org/10.1155/2010/605163>
- American Diabetes Association (ADA). Standards of medical care in diabetes- 2018". *Diabetes Care*. 2018;41(Suppl 1):S13–S27, doi: <https://doi.org/10.2337/dc18-S002>
- Rayanagoudar G, Hashi AA, Zamora J et al (2016) Quantification of the type 2 diabetes risk in women with gestational diabetes: a systematic review and meta-analysis of 95,750 women. *Diabetologia* 59:1403–1411. <https://doi.org/10.1007/s00125-016-3927-2>
- Burlina S, Dalfrà MG, Lapolla A. Clinical and biochemical approach to predicting post-pregnancy metabolic decompensation. *Diabetes Res Clin Pract*, 2018;145:178–183. DOI:10.1016/j.diabres.2018.02.035. DOI: <https://doi.org/10.1016/j.diabres.2018.02.035>
- Yessoufou A, Moutairou K. Maternal Diabetes in Pregnancy: Early and Long-Term Outcomes on the Offspring and the Concept of "Metabolic Memory. *Experimental Diabetes Research*, 2011; 2011: Article ID 218598. <https://doi.org/10.1155/2011/218598>
- Metzger BE (2009) The HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. Associations with neonatal anthropometrics. *Diabetes* 58:453–459. <https://doi.org/10.2337/db08-1112>
- Freinkel N (1980) Banting Lecture 1980: of pregnancy and progeny. *Diabetes* 29:1023–1035
- Farahvar S, Walfisch A, Sheiner E (2019) Gestational diabetes risk factors and long-term consequences for both mother and offspring: a literature review. *Expert Rev Endocrinol Metab* 14(1):63–74. <https://doi.org/10.1080/17446651.2018.1476135>
- Franzago M, Fraticelli F, Stuppia L, Vitacolonna E (2019) Nutrigenetics, epigenetics and gestational diabetes: consequences in mother and child. *Eigenetics* 14(3):215–235 <https://doi.org/10.1080/15592294.2019.1582277>
- Hod M, Kapur A, Sacks A et al (2015) The international Federation of Gynecology and Obstetrics (FIGO). Initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. *J Gynecol Obstet* 131(Suppl 3):S173–S211
- Diabetes G International Diabetes Federation – Home. Available online at www.idf.org/our-activities/care-prevention/gdm
- Zhao J, Weiler HA. Long-term effects of gestational diabetes on offspring health are more pronounced in skeletal growth than body composition and glucose tolerance. *Br J Nutr*, 2010;104(11):1641–9. doi: 10.1017/S0007114510002631.
- Damm P1, Houshmand-Oeregaard A, Kelstrup L, et al. Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark. *Diabetologia*, 2016;59 (7):1396–1399. doi: <https://doi.org/10.1007/s00125-016-3985-5>.
- Clausen TD, Mathiesen ER, Hansen T et al (2008) High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. *Diabetes Care* 31:340–346. <https://doi.org/10.2337/dc07-1596>
- Assche FAV, Holemans K, Aerts L (2011) Long-term consequences for offspring of diabetes during pregnancy. *British Medical Bulletin* 60(1):173–182 <https://doi.org/10.1093/bmb/60.1.173>
- International Diabetes Federation. *Diabetes Atlas* 8th ed., 2017. Available online at <http://fmdiabetes.org/wp-content/uploads/2018/03/IDF-2017.pdf>
- Kaaja R, Rönnemaa T (2008) Gestational Diabetes: Pathogenesis and Consequences to Mother and Offspring. *Rev Diabet Stud*. 5(4):194–202. <https://doi.org/10.1900/RDS.2008.5.194>
- Shu L, Sauter NS, Schulthess FT, Matveyenko AV, Oberholzer. Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. *Diabetes*, 2008; 57: 645–653.
- MacDonald PE, Ha XF, Wang J, Smukler SR, Sun AM, Gaisano HY (2001) Members of the Kv1 and Kv2 voltage-dependent K(+) channel families regulate insulin secretion. *Mol Endocrinol* 15(8):1423–1435. <https://doi.org/10.1210/mend.15.8.0685>
- Huerta-Chagoya A, Vázquez-Cárdenas P, Moreno-Macías H, Tapia-Maruri L, Rodríguez-Guillén R, López-Vite E (2015) Genetic determinants for gestational diabetes mellitus and related metabolic traits in Mexican women. *PLoS one* 10(5):e0126408. <https://doi.org/10.1371/journal.pone.0126408>
- Prokopenko I, Langenberg C, Florez JC et al (2009) Variants in MTNR1B influence fasting glucose levels. *Nature genetics* 41(1):77–81. 1906907
- Shang M, Wen Z (2018) Increased placental IGF-1/mTOR activity in macrosomia born to women with gestational diabetes. *Diabetes Research and Clinical Practice* 146:211–219 <https://doi.org/10.1016/j.diabres.2018.10.017>
- Casellas A, Mallol C, Salavert A, Jimenez V, Garcia M, Agudo J (2015) Insulin-like Growth Factor 2 Overexpression Induces β -Cell Dysfunction and Increases Beta-cell Susceptibility to Damage. *The Journal of Biological Chemistry* 290:16772–16785. <https://doi.org/10.1074/jbc.M115.642041>
- Ramirez VI, Miller E, Meireles CL, Gelfond J, Krummel DA, Powell TL (2014) Adiponectin and IGF1P-1 in the development of gestational diabetes in obese mothers. *BMJ Open Diabetes Research and Care* 2:e000010. <https://doi.org/10.1136/bmjdr-2013-000010>
- DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG (2008) Gender-specific changes in bone turnover and skeletal architecture in IGF1P2-null mice. *Endocrinology* 149:2051–2061. <https://doi.org/10.1210/en.2007-1068>
- Chon SJ, Kim SY, Cho NR, Min DL, Hwang YJ, Mamura M (2013) Association of variants in PPAR γ 2, IGF2BP2, and KCNQ1 with a susceptibility to gestational diabetes mellitus in a Korean population. *Yonsei Medical Journal* 54(2):352–357. <https://doi.org/10.3349/yjm.2013.54.2.352>
- Schwanstecher C, Meyer U, Schwanstecher M (2002) K(IR)6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic beta-cell ATP-sensitive K(+) channels. *Diabetes* 51:875–879. <https://doi.org/10.2337/diabetes.51.3.875>
- Ober C, Xiang KS, Thisted RA, Indovina KA, Wason CJ, Dooley S (1989) Increased risk for gestational diabetes mellitus associated with insulin receptor and insulin-like growth factor II restriction fragment length polymorphisms. *Genet Epidemiol* 6:559–569
- Cearine AM, Lin EE, Lumelsky DN, Iyer R, Kuruvilla R (2018) Adb2 controls glucose homeostasis by developmental regulation of pancreatic islet vasculature. *ELife* 7:e39689. <https://doi.org/10.7554/elife.39689>
- Guan L, Cui X, Zhou H (2018) Meta-analysis of the association between the Trp64Arg polymorphism of the beta-3 adrenergic receptor and susceptibility to gestational diabetes mellitus. *J Obstet Gynaecol* 38(2):172–176. <https://doi.org/10.1080/01443615.2017.1331339>
- Feng Y, Jiang CD, Chang AM et al (2019) Interactions among insulin resistance, inflammation factors, obesity-related gene polymorphisms, environmental risk factors, and diet in the development of gestational diabetes mellitus. *J Matern Fetal Neonatal Med*. 32(2):339–347. <https://doi.org/10.1080/14767058.2018.1446207>
- Kapoor RR, Flanagan SE, James CT, McKiernan J, Thomas AM, Harner SC (2011) Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABC8/KCNJ11 mutations. *Diabetologia* 54(10):2575–2583. <https://doi.org/10.1007/s00125-011-2207-4>
- Castro-Martínez AG, Sánchez-Corona J, Vázquez-Vargas AP, García-Zapién AG, López-Quintero A, Villalpando-Velazco HJ. Association analysis of calpain 10 gene variants/haplotypes with gestational diabetes mellitus among Mexican women. *Cell Mol Biol (Noisy-le-grand)*. 2018; 28;64(3):81–86. doi: <https://doi.org/10.14715/cmb/2018.64.3.13>.
- Megia A, Gallart L (2004) Fernández-Real J-M, Vendrell J, Simón I, Gutierrez C. Mannose-Binding Lectin Gene Polymorphisms Are Associated with Gestational Diabetes Mellitus. *The Journal of Clinical Endocrinology & Metabolism* 89(10):5081–5087 <https://doi.org/10.1210/jc.2004-0211>
- Catalano PM (2014) Trying to understand gestational diabetes. *Diabet. Med* 31:273–281. <https://doi.org/10.1111/dme.12381>
- Yang Q, Graham TE, Mody N et al (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature* 436: 356–362
- Shimin Hu, Shujuan Ma, Xun Li, et al. Relationships of SLC24A4, RBP4, PCK1, and PI3K Gene Polymorphisms with Gestational Diabetes Mellitus in a Chinese Population. *BioMed Research International*, 2018; 2019:Article ID 7398063. <https://doi.org/10.1155/2019/7398063>.

39. Shimin H, Junxia Y, Yiping Y, Guilian Y, Hui Z, Xun L (2019) Association of polymorphisms in STRA6 gene with gestational diabetes mellitus in a Chinese Han population. *Medicine* 98(11):e14885. <https://doi.org/10.1097/MD.00000000000014885>
40. Zhu B, Huang K, Yan S, et al. VDR Variants rather than Early Pregnancy Vitamin D Concentrations Are Associated with the Risk of Gestational Diabetes: The Ma'anshan Birth Cohort (MABC) Study. *J. Diabetes Res*, 2019; 2019: Article ID 8313901. <https://doi.org/10.1155/2019/8313901>.
41. Apaydin M, Beyse S, Eyerci N, Pinarli FA, Ulubay M, Kizilgul M. The VDR gene FokI polymorphism is associated with gestational diabetes mellitus in Turkish women. *BMC Medical Genetics*, 2019; 20: Article number: 82. DOI <https://doi.org/10.1186/s12881-019-0820-0>
42. Wang K, Chen Q, Feng Y, et al. Single Nucleotide Polymorphisms in CDKAL1 Gene Are Associated with Risk of Gestational Diabetes Mellitus in Chinese Population. *J Diabetes Res*, 2019; 2019: Article ID 3618103. <https://doi.org/10.1155/2019/3618103>.
43. Okruszko A, Kinalski M, Kuźmicki M, Mirończuk K, Wawrusiewicz-Kurylonek N, Kretowski KIA (2007) Glucokinase gene mutations in gestational diabetes in Polish population. Prediction of diabetes mellitus development after delivery. *Przegl Lek* 64(6):401–405
44. Mei J, Liao S, Liu Y, Tan Y, Wang H, Liang Y (2015) Association of variants in CDKN2A/2B and CDKAL1 genes with gestational insulin sensitivity and disposition in pregnant Han Chinese women. *J Diabetes Investig* 6(3):295–301. <https://doi.org/10.1111/jdi.12315>
45. Wang Y, Nie M, Li W et al (2011) Association of Six Single Nucleotide Polymorphisms with Gestational Diabetes Mellitus in a Chinese Population. *PLoS ONE* 6(11):e26953 <https://doi.org/10.1371/journal.pone.0026953>
46. Cho YM, Kim TH, Lim S, Choi SH, Shin HD, Lee HK (2009) Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population. *Diabetol* 52:253–261. <https://doi.org/10.1007/s00125-008-1196-4>
47. Seman NA, Mohamad WN, Östenson CG, et al. Increased DNA methylation of the SLC30A8 gene promoter is associated with type 2 diabetes in a Malay population. *Clin. Epigenetics*, 2015; 7: 30. <https://doi.org/10.1186/s13148-015-0049-5>.
48. Marcello MA, Calixto AR, de Almeida JF, et al. Polymorphism in LEP and LEPR May Modify Leptin Levels and Represent Risk Factors for Thyroid Cancer. *Int. J. Endocrinol.* 2015: 173218. <https://doi.org/10.1155/2015/173218>.
49. Lin R, Ju H, Yuan Z, Zeng L, Sun Y, Su Z (2017) Association of maternal and fetal LEPR common variants with maternal glycemic traits during pregnancy. *Sci Rep* 7(1):3112. <https://doi.org/10.1038/s41598-017-03518-x>
50. Watanabe RM, Xiang AH, Allayee H, et al. Variation in the P2-promoter region of hepatocyte nuclear factor-4a (HNF4A) is associated with β -cell function in Mexican American families of a proband with gestational diabetes. *Diabetes*, 2005; 54 (supplement 1): A28.
51. Ridderstråle M, Groop L (2009) Genetic dissection of type 2 diabetes. *Molecular and Cellular Endocrinology* 297(1-2):10–17
52. Ategbro JM, Grissa O, Yessoufou A, Hichami A, Dramane KL, Moutairou K (2006) Modulation of adipokines and cytokines in gestational diabetes and macrosomia. *J Clin Endocrinol Metab.* 91:4137–4143
53. Toppings NB, McMillan JM, Au P, Suchowersky O, Donovan LE. Wolfram Syndrome: A Case Report and Review of Clinical Manifestations, Genetics Pathophysiology, and Potential Therapies. *Case Reports in Endocrinol*, 2018; 2018: Article ID 9412676 doi:<https://doi.org/10.1155/2018/9412676>.
54. Vana DR, Adapa D, Prasad VSS, Choudhury A, Ahuja G. Diabetes mellitus types: Key genetic determinants and risk assessment. *Genet Mol Res*, 2019; 18 (2): gmr16039952.
55. Kwak SH, Park BL, Kim H, German MS, Go MJ, Jung HS. Association of Variations in TPH1 and HTR2B with Gestational Weight Gain and Measures of Obesity. *Obesity*, 2012; 20 (1). <https://doi.org/10.1038/oby.2011.253>
56. Oh CM, Park S, Kim H (2016) Serotonin as a New Therapeutic Target for Diabetes Mellitus and Obesity. *Diabetes Metab J* 40(2):89–98. <https://doi.org/10.4093/dmj.2016.40.2.89>
57. Beyse S, Eyerci N, Ulubay M, Caliskan M, Kizilgul M, Hafizoğlu M. Maternal genetic contribution to pre-pregnancy obesity, gestational weight gain, and gestational diabetes mellitus. *Diabetol Metabol Synd*, 2019; 11: Article number: 37. <https://doi.org/10.1186/s13098-019-0434-x>
58. Pollin TI, Jablonski KA, McAteer JB et al (2011) Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the GCKR Pro446Leu polymorphism. *J Clin Endocrinol Metab* 96:E1142–E1147. <https://doi.org/10.1210/jc.2010-2324>
59. Grimsby J, Coffey JW, Dvorozniak MT, Magram J, Li G, Matschinsky FM. Characterization of glucokinase regulatory protein-deficient mice. *J Biol Chem*, 2000; 275 :7826 –7831. doi: <https://doi.org/10.1074/jbc.275.11.7826>
60. Zheng L, Li C, Qi WH et al (2017) Expression of macrophage migration inhibitory factor gene in placenta tissue and its correlation with gestational diabetes mellitus. *Zhonghua yi xue za zhi* 97:3388–3391
61. Kawai VK, Levinson RT, Adefurin A, Kurnik D, Collier SP, Conway D (2017) Variation in the α 2A-adrenergic receptor gene and risk of gestational diabetes. *Pharmacog* 18(15):1381–1386. <https://doi.org/10.2217/pgs-2017-0079>
62. Leitner M, Fragner L, Danner S, Holeschovsky N, Leitner K, Tischler S (2017) Combined metabolomic analysis of plasma and urine reveals AHBA, Tryptophan and Serotonin metabolism as potential risk factors in Gestational Diabetes Mellitus (GDM). *Front Mol Biosci* 4:84. <https://doi.org/10.3389/fmolb.2017.00084>
63. Beyse S, Eyerci N, Ulubay M, Caliskan M, Kizilgul M, Hafizoğlu M. Maternal genetic contribution to pre-pregnancy obesity, gestational weight gain, and gestational diabetes mellitus. *Diabetol Metab Synd*, 2019; 11: Article number: 37. <https://doi.org/10.1186/s13098-019-0434-x>
64. Mellado-Gil JM, Fuente-Martín E, Lorenzo PI, Cobo-Vuilleumier N, López-Noriega L, Martín-Montalvo A. The type 2 diabetes-associated HMG20A gene is mandatory for islet beta cell functional maturity. *Cell Death & Disease*, 2018; 9: Article number: 279.
65. Hodson DJ, Mitchell RK, Marselli L, Pullen TJ, Gimeno Brias S, Semplici F (2014) ADCY5 couples glucose to insulin secretion in human islets. *Diabetes* 63(9):3009–3021. <https://doi.org/10.2337/db13-1607>
66. Mojtaba E, Mahdi K, Mehdi KJR, Amir S (2011) Serum interleukin-1 beta plays an important role in insulin secretion in type II diabetic. *Inter J Bio* 1(3):93–99
67. Meier JJ, Ritzel RA, Maedler K, Gurlo T, Butler PC (2006) Increased vulnerability of newly forming beta cells to cytokine-induced cell death. *Diabetolog* 49:83–89. <https://doi.org/10.1007/s00125-005-0069-3>
68. Kang J, Liu C-H, Lee C-N, Li H-Y, Yang C-W, Huang S-C (2019) Novel Interleukin-10 Gene Polymorphism Is Linked to Gestational Diabetes in Taiwanese Population. *Front. Genet* 10:89. <https://doi.org/10.3389/fgene.2019.00089>
69. Martín-Montalvo A, López-Noriega L, Jiménez-Moreno C, Herranz A, Lorenzo PI, Cobo-Vuilleumier N (2019) Transient PAX8 Expression in Islets During Pregnancy Correlates With β -Cell Survival, Revealing a Novel Candidate Gene in Gestational Diabetes Mellitus. *Diabetes* 68(1):109–118 <https://doi.org/10.2337/db18-0285>
70. Takhshid MA, Haem Z, Aboualazadeh F (2015) The association of circulating adiponectin and + 45 T/G polymorphism of adiponectin gene with gestational diabetes mellitus in Iranian population. *J Diabetes Metab Disord* 14:30. <https://doi.org/10.1186/s40200-015-0156-z>
71. Hasanvand Z, Sadeghi A, Rezvanfar MR, Goodarzi MT, Rahmannedhad G, Mashayekh FJ (2018) Association between chemerin rs17173608 and rs4721 gene polymorphisms and gestational diabetes mellitus in Iranian pregnant women. *Gene* 649:87–92 <https://doi.org/10.1016/j.gene.2018.01.061>
72. Ademoglu E, Berberoglu Z, Dellal FD, Ariel MK, Kose A, Candan Z. Higher Levels of Circulating Chemerin in Obese Women with Gestational Diabetes Mellitus. *Acta Endocrinologica (Buc)*, 2015; XI (1): 32-37. doi: <https://doi.org/10.4183/aeb.2015.32>.
73. Steppan CM, Bailey ST, Bhat S et al (2001) The hormone resistin links obesity to diabetes. *Nature* 409:307–312
74. Aslan M, Celik O, Celik N et al (2012) Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus. *Endocrine* 41:424–429
75. Franz M, Polterauer M, Springer S, Kuessel L, Haslinger P, Worda C (2018) Maternal and neonatal omentin-1 levels in gestational diabetes. *Arch gynecol obst* 297(4):885–889. <https://doi.org/10.1007/s00404-018-4652-5>
76. Ferreira AF, Rezende JC, Vaikousi E et al (2011) Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus. *Clin Chem* 57: 609–613
77. Mellado-Gil JM, Fuente-Martín E, Lorenzo PI, Cobo-Vuilleumier N, López-Noriega L, Martín-Montalvo A. The type 2 diabetes-associated HMG20A gene is mandatory for islet beta cell functional maturity. *Cell Death & Disease*, 2018; 9:Article number: 279.
78. Ding M, Chavarro J, Olsen S, Lin Y, Ley SH, Bao W. Genetic variants of gestational diabetes mellitus: a study of 112 SNPs among 8722 women in

- two independent populations. *Diabetolog*, 2018; 61 (8): 1758–1768. <https://doi.org/10.1007/s00125-018-4637-8>.
79. Khan IA, Shaik NA, Pasupuleti N, Chav S, Jahan P, Hasan Q (2015) Screening of mitochondrial mutations and insertion–deletion polymorphism in gestational diabetes mellitus in the Asian Indian population. *Saudi J Bio Sci* 22(3):243–248 <https://doi.org/10.1016/j.sjbs.2014.11.001>
 80. Banerjee RR, Cyphert HA, Walker EM, Chakravarthy H, Peiris H, Gu X (2016) Gestational Diabetes Mellitus From Inactivation of Prolactin Receptor and MafB in Islet β -Cells. *Diabetes* 65(8):2331–2341. <https://doi.org/10.2337/db15-1527>
 81. Zha W, Ho HTB, Hu T, Hebert MF, Wang MJ. Serotonin transporter deficiency drives estrogen-dependent obesity and glucose intolerance. *Sci Rep*, 2017; 7: Article number: 1137. DOI <https://doi.org/10.1038/s41598-017-01291-5>.
 82. Leipold H, Knoefler M, Gruber C, Klein K, Haslinger P, Worda C (2006) Plasminogen activator inhibitor 1 gene polymorphism and gestational diabetes mellitus. *Obstet Gynecol* 107(3):651–656. <https://doi.org/10.1097/01.AOG.0000199953.27961.f9>
 83. Stuebe AM, Wise A, Nguyen T, Herring A, North KE, Siega-Riz AM (2014) Maternal genotype and gestational diabetes. *Am J Perinatol*. 31(1):69–76. <https://doi.org/10.1055/s-0033-1334451>
 84. Chagnon MJ, Elchebly M, Uetani N, Dombrowski L, Cheng A, Mooney RA (2006) Altered glucose homeostasis in mice lacking the receptor protein tyrosine phosphatase sigma. *Can J Physiol Pharmacol* 84:755–763. <https://doi.org/10.1139/y06-020>
 85. Alamolhoda SH, Yazdkhasti M, Namdari M, Zakariyai SJ, Mirabi P (2019) Association between C-reactive protein and gestational diabetes: a prospective study. *J Obstet Gynaecol* 9:1–5. <https://doi.org/10.1080/01443615.2019.1631767>
 86. Zhang YH, Van Hove JL, McCabe ER, Dipple KM (2015) Gestational Diabetes Associated with a Novel Mutation (378-379insTT) in the Glycerol Kinase Gene. *Mol Genet Metab Rep* 4:42–45. <https://doi.org/10.1016/j.jmgmr.2015.06.004>
 87. Xu T, Shi Y, Liu J, Liu Y, Zhu A, Xie C (2017) The rs10229583 polymorphism near paired box gene 4 is associated with gestational diabetes mellitus in Chinese women. *J Inter Med Res* 46(1):116–121. <https://doi.org/10.1177/0300060517714934>
 88. Gong M, Yu Y, Liang L, Vuralli D, Froehler S, Kuehnen P (2019) HDAC4 mutations cause diabetes and induce β -cell FoxO1 nuclear exclusion. *Mol Genet Gen med* 7(5):e602. <https://doi.org/10.1002/mgg3.602>
 89. Farhan S, Handisurya A, Todoric J, Tura A, Pacini G, Wagner O (2012) Fetuin-A Characteristics during and after Pregnancy: Result from a Case Control Pilot Study. *Inter J Endocrinol* 896736. <https://doi.org/10.1155/2012/896736>
 90. Kralisch S, Hoffmann A, Lössner U (2017) Kratzsch J3, Blüher M, Stumvoll M. Regulation of the novel adipokines/ hepatokines fetuin A and fetuin B in gestational diabetes mellitus. *Metab* 68:88–94. <https://doi.org/10.1016/j.metabol.2016.11.017>
 91. Bonakdaran S, Khorasani ZM, Jafarzadeh F (2017) Increased Serum Level of Fgf21 in Gestational Diabetes Mellitus. *Acta Endocrinol* 13(3):278–281. <https://doi.org/10.4183/aeb.2017.278>
 92. Xie K, Chen T, Zhang Y, Wen J, Cui X, You L. Association of rs10830962 polymorphism with gestational diabetes mellitus risk in a Chinese population. *Sci Rep*, 2019; 9:Article number: 5357. DOI <https://doi.org/10.1038/s41598-019-41605-3>
 93. Huerta-Chagoya A, Vázquez-Cárdenas P, Moreno-Macías H et al (2015) Genetic Determinants for Gestational Diabetes Mellitus and Related Metabolic Traits in Mexican Women. *PLoS ONE* 10(5):e0126408 <https://doi.org/10.1371/journal.pone.0126408>
 94. Wu L, Cui L, Tam W et al (2016) Genetic variants associated with gestational diabetes mellitus: a meta-analysis and subgroup analysis. *Sci Rep* 6:30539. <https://doi.org/10.1038/srep30539>
 95. Shaat N, Lernmark A, Karlsson E et al (2007) A variant in the transcription factor 7-like 2 (TCF7L2) gene is associated with an increased risk of gestational diabetes mellitus. *Diabetologia* 50:972–979
 96. Adeyemo AA, Zaghoul NA, Chen G et al (2019) ZRANB3 is an African-specific type 2 diabetes locus associated with beta-cell mass and insulin response. *Nat Commun* 10:3195. <https://doi.org/10.1038/s41467-019-10967-7>
 97. Lin P-C, Lin W-T, Yeh Y-H, Wung S-F (2016) Transcription Factor 7-Like 2 (TCF7L2) rs7903146 Polymorphism as a Risk Factor for Gestational Diabetes Mellitus: A Meta-Analysis. *PLoS One* 11(4):e0153044 <https://doi.org/10.1371/journal.pone.0153044>
 98. Lauenborg J, Grarup N, Damm P et al (2009) Common Type 2 Diabetes Risk Gene Variants Associate with Gestational Diabetes. *J Clin Endocrinol & Metab* 94(1):145–150 <https://doi.org/10.1210/jc.2008-1336>
 99. Kawai VK, Levinson RT, Adefurin A et al (2017) A genetic risk score that includes common type 2 diabetes risk variants is associated with gestational diabetes. *Clin Endocrinol* 87(2):149–155. <https://doi.org/10.1111/cen.13356>
 100. Kwak SH, Kim TH, Cho YM, Choi SH, Jang HC, Park KS (2010) Polymorphisms in KCNQ1 are associated with gestational diabetes in a Korean population. *Horm Res Paediatr*. 74:333–338
 101. Fatima SS, Chaudhry B, Khan TA, Farooq S. KCNQ1 rs2237895 polymorphism is associated with Gestational Diabetes in Pakistani Women. *Pak J Med Sci*. 2016 Nov-Dec;32(6):1380-1385. doi: <https://doi.org/10.12669/pjms.326.11052>.
 102. Kwak SH, Jang HC, Park KS (2012) Finding Genetic Risk Factors of Gestational Diabetes. *Genomics Inform*. 10(4):239–243. <https://doi.org/10.5808/GI.2012.10.4.239>
 103. Ding M (2018) Chavarro J1, Olsen S, Lin Y, Ley SH1, Bao W, et al. Genetic Variants of Gestational Diabetes Mellitus: a Study of 112 SNPs Among 8,722 Women in Two Independent Populations. *Diabetologia*. 61(8):1758–1768. <https://doi.org/10.1007/s00125-018-4637-8>
 104. Alharbi KK, Al-Sulaiman AM, Bin Shedaik MK, et al. MTNR1B genetic polymorphisms as risk factors for gestational diabetes mellitus: a case-control study in a single tertiary care center. *Ann Saudi Med*. 2019; 39(5): 309-318. doi: <https://doi.org/10.5144/0256-4947.2019.309>.
 105. Mansoori Y, Daraei A, Naghizadeh MM, Salehi R (2015) Significance of a common variant in the CDKAL1 gene with susceptibility to type 2 diabetes mellitus in Iranian population. *Adv Biomed Res* 4:45. <https://doi.org/10.4103/2277-9175.151256>
 106. Shaat N, Ekelund M, Lernmark A et al (2005) Association of the E23K polymorphism in the KCNJ11 gene with gestational diabetes mellitus. *Diabetolog* 48:2544–2551
 107. Fallucca F, Dalfrà MG, Sciuillo E et al (2006) Polymorphisms of insulin receptor substrate 1 and beta3-adrenergic receptor genes in gestational diabetes and normal pregnancy. *Metab* 55:1451–1456
 108. Alharbi KK, Khan IA, Abotalib Z, Al-Hakeem MM. Insulin Receptor Substrate-1 (IRS-1) Gly927Arg: Correlation with Gestational Diabetes Mellitus in Saudi Women. *BioMed Res Intern*, 2014, Article ID 146495. <https://doi.org/10.1155/2014/146495>.
 109. Rosta K, Al-Aissa Z, Hadarits O et al (2017) Association study with 77 SNPs confirms the robust role for the rs10830963/G of MTNR1B variant and identifies two novel associations in gestational diabetes mellitus development. *PLoS One* 12:e0169781
 110. Cho YM, Kim TH, Lim S et al (2009) Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population. *Diabetolog* 52(2):253–261
 111. Wang Y, Nie M, Li W et al (2011) Association of six single nucleotide polymorphisms with gestational diabetes mellitus in a Chinese population. *PLoS One* 6(11):e26953
 112. Lauenborg J, Grarup N, Damm P et al (2009) Common type 2 diabetes risk gene variants associate with gestational diabetes. *J Clin Endocrinol Metab* 94(1):145–150
 113. Stuebe A, Wise A, Nguyen T, Herring A, North K, Siega-Riz A (2013) Maternal Genotype and Gestational Diabetes. *Am. J. Perinatol*. 31:069–076
 114. Jamalpour S, Zain SM, Mosavat M, Mohamed Z, Omar S.Z. A case-control study and meta-analysis confirm glucokinase regulatory gene rs780094 is a risk factor for gestational diabetes mellitus. *Gene* 2018, 650, 34–40.
 115. Anghelbem-Oliveira MI, Webber S, Alberton D et al (2017) The GCKR Gene Polymorphism rs780094 is a Risk Factor for Gestational Diabetes in a Brazilian Population. *J. Clin. Lab. Anal* 31:e22035
 116. Bonakdaran S, Khorasani ZM, Jafarzadeh F (2017) Increased Serum Level of Fgf21 in Gestational Diabetes Mellitus. *Acta Endocrinol (Buchar)*. 13(3):278–281. <https://doi.org/10.4183/aeb.2017.278>
 117. Chen C, Cheung BM, Tso AW et al (2011) High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. *Diabetes Care*. 34(9):2113–2115. <https://doi.org/10.2337/dc11-0294>
 118. Nitert D, Barrett HL, Kubala MH et al (2014) Increased Placental Expression of Fibroblast Growth Factor 21 in Gestational Diabetes Mellitus. *J Clin Endocrinol & Metab* 99(4):E591–E598 <https://doi.org/10.1210/jc.2013-2581>

119. Rissanen J, Markkanen A, Karkkainen P et al (2000) Sulfonylurea receptor 1 gene variants are associated with gestational diabetes and type 2 diabetes but not with altered secretion of insulin. *Diabetes Care* 23:70–73
120. Hasanvand Z, Sadeghi A, Rezvanfar MR, Goodarzi MT, Rahmannedhad G, Mashayekhi FJ (2018) Association between chemerin rs17173608 and rs4721 gene polymorphisms and gestational diabetes mellitus in Iranian pregnant women. *Gene*. 649:87–92. <https://doi.org/10.1016/j.gene.2018.01.061>
121. Litou H, Anastasiou E, Thalassinou L et al (2007) Increased prevalence of VNTR III of the insulin gene in women with gestational diabetes mellitus (GDM). *Diabetes Res Clin Pract* 76:223–228
122. Handy DE, Castro R, Loscalzo J (2011) Epigenetic Modifications: Basic Mechanisms and Role in Cardiovascular Disease. *Circulation*. 123(19):2145–2156. <https://doi.org/10.1161/CIRCULATIONAHA.110.956839>
123. Feil R, Fraga MF (2011) Epigenetics and the environment: Emerging patterns and implications. *Nat Rev Genet* 13:97–109. <https://doi.org/10.1038/nrg3142>
124. Ordovas JM, Smith CE (2010) Epigenetics and cardiovascular disease. *Nat Rev Cardiol* 7:510–519. <https://doi.org/10.1038/nrcardio.2010.104>
125. Stankov K, Benc D, Draskovic D (2013) Genetic and epigenetic factors in etiology of diabetes mellitus type 1. *Pediatr* 132:1112–1122
126. Xie Z, Chang C, Zhou Z (2014) Molecular mechanisms in autoimmune type 1 diabetes: a critical review. *Clin Rev Allergy Immunol* 47:174–192
127. Kimmins S, Sassone-Corsi P (2005) Chromatin remodelling and epigenetic features of germ cells. *Nature* 434(7033):583–589
128. Kang J, Lee C-N, Li H-Y, Hsu K-H, Wang S-H, Lin S-Y (2018) Association of Interleukin-10 Methylation Levels With Gestational Diabetes in a Taiwanese Population. *Front Genet* 9:222. <https://doi.org/10.3389/fgene.2018.00222>
129. Jacovetti C, Abderrahmani A, Parnaud G, Jonas JC, Peyot ML, Cornu M (2012) MicroRNAs contribute to compensatory β cell expansion during pregnancy and obesity. *J Clin Invest* 122(10):3541–3551. <https://doi.org/10.1172/JCI64151>
130. Stirn L, Huypens P, Sass S, Batra R, Fritsche L, Brucker S. Maternal whole blood cell miRNA-340 is elevated in gestational diabetes and inversely regulated by glucose and insulin. *Sci Rep*, 2018; 8:1366-1378. | DOI:<https://doi.org/10.1038/s41598-018-19200-9>.
131. Jo H, Eckel SP, Chen J-C, Cockburn M, Martinez MP, Chow T (2019) Associations of gestational diabetes mellitus with residential air pollution exposure in a large Southern California pregnancy cohort. *Environ Inter* 130: 104933–104939 <https://doi.org/10.1016/j.envint.2019.104933>
132. Lodovici M, Bigagli E. Oxidative stress and air pollution exposure. *J Toxicol*, 2011; (2011): Article 487074
133. Saldana TM, Basso O, Hoppin JA, Baird DD, Knott C, Blair A (2007) Pesticide Exposure and Self-Reported Gestational Diabetes Mellitus in the Agricultural Health Study. *Diabetes Care* 30(3):529–534. <https://doi.org/10.2337/dc06-1832>
134. Vu BG, Stach CS, Kulhankova K, Salgado-Pabón W, Klingelutz AJ, Schlievert PM. Chronic Superantigen Exposure Induces Systemic Inflammation, Elevated Bloodstream Endotoxin, and Abnormal Glucose Tolerance in Rabbits: Possible Role in Diabetes. *mBio*, 2015; 6 (2): e02554-14 DOI: <https://doi.org/10.1128/mBio.02554-14>.
135. Crusell MKW, Hansen TH, Nielsen T, Allin KH, Rühlemann MC, Damm P (2018) Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum. *Microbiome* 6: 89 <https://doi.org/10.1186/s40168-018-0472-x>
136. Mokkala K, Røytiö H, Munukka E, Pietilä S, Ekblad U, Rönnemaa T (2016) Gut Microbiota Richness and Composition and Dietary Intake of Overweight Pregnant Women Are Related to Serum Zonulin Concentration, a Marker for Intestinal Permeability. *J Nutr* 146(9):1694–1700. <https://doi.org/10.3945/jn.116.235358>
137. Duke-NUS Medical School. Association between insufficient sleep, gestational diabetes mellitus discovered. *ScienceDaily*. www.sciencedaily.com/releases/2017/01/170109092634.htm (accessed October 26, 2019).
138. Mak JKL, Pham NM, Lee AH, Tang L, Pan X-F, Binns CW. Dietary patterns during pregnancy and risk of gestational diabetes: a prospective cohort study in Western China. *Nutr J*, 2018; 17:Article number: 107. DOI <https://doi.org/10.1186/s12937-018-0413-3>
139. Cai D, Liu H, Hu Y, Jiang Y, Zhao R Gestational Betaine, Liver Metabolism, and Epigenetics. In: Patel V., Preedy V. (eds) *Handbook of Nutrition, Diet, and Epigenetics*. Springer, Cham. 2017. DOI https://doi.org/10.1007/978-3-319-31143-2_82-1
140. Sivitz W. Mitochondrial Dysfunction in Obesity and Diabetes. *US Endocrinol*, 2010; 6 (1): 20-27 DOI: <https://doi.org/10.17925/USE.2010.06.1.20>.
141. R'onn T, Poulsen P, Hansson O, et al. Age influences DNA methylation and gene expression of COX7A1 in human skeletal muscle. *Diabetolog*, 2008; 51: 1159{1168. DOI: <https://doi.org/10.1007/s00125-008-1018-8>.
142. Makgoba M, Savvidou M, Steer P (2012) An analysis of the interrelationship between maternal age, body mass index and racial origin in the development of gestational diabetes mellitus. *BJOG* 119:276–282. <https://doi.org/10.1111/j.1471-0528.2011.03156.x>
143. Ming W, Ding W, Zhang CJP, Zhong L, Long Y, Li Z. The effect of exercise during pregnancy on gestational diabetes mellitus in normal-weight women: a systematic review and meta-analysis. *BMC Pregnancy and Childbirth*, 2018; 18: Article number: 440. DOI <https://doi.org/10.1186/s12884-018-2068-7>.
144. Eriksson KF, Lindgärde F. Poor physical fitness, and impaired early insulin response but late hyperinsulinaemia, as predictors of NIDDM in middleaged Swedish men. *Diabetolog*, 1996; 39:573-579.
145. Grazioli E, Dimauro I, Mercatelli N et al (2017) Physical activity in the prevention of human diseases: role of epigenetic modifications. *BIC Genomics* 18(Suppl 8):802. <https://doi.org/10.1186/s12864-017-4193-5>
146. World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Geneva; 2013. http://www.who.int/diabetes/publications/Hyperglycaemia_In_Pregnancy/en/
147. United Kingdom National Health Service. Overview: Gestational Diabetes. Updated 2019. Available at <https://www.nhs.uk/conditions/gestational-diabetes/>.
148. United States National Institute of Health. Tests & Diagnosis for Gestational Diabetes. Updated 2017. Available at <https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/gestational/tests-diagnosis>
149. Farghaly TA, Helmy NA, Abbas AM, Ahmed AGM C-reactive protein as a screening test for gestational diabetes mellitus in first-trimester of pregnancy: a prospective cohort study. *Int J Reprod Contracept Obstet Gynecol*, 2018;7:4798-803. DOI <https://doi.org/10.18203/2320-1770.ijrcog20184922>
150. Schaible B, Calhoun BC, Bush S, Ramser B, Seybold DJ, Broce M. Hemoglobin A1c as a screening strategy for gestational diabetes. *Med Dent Res*, 2018; 1 (1): 1-4. DOI: <https://doi.org/10.15761/MDR.1000103>
151. Fitriá N, van Asselt ADI, Postma MJ (2019) Cost-effectiveness of controlling gestational diabetes mellitus: a systematic review. *Eur J Health Eco* 20(3): 407–417. <https://doi.org/10.1007/s10198-018-1006-y>
152. Marseille E, Lohse N, Jiwani A, Hod M, Seshiah V, Jainik CS. The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel. *J Maternal-Fetal & Neonat Med*, 2013; 26 (8). <https://doi.org/10.3109/14767058.2013.765845>.
153. Saccone G, Caissutti C, Khalifeh MDA, Scifres C, Simhan HN (2017) One Step versus Two Step approach for gestational diabetes screening: systematic review and meta-analysis of the randomized trials. *Journal of Maternal-Fetal and Neonat Med* 32(8):1–211. <https://doi.org/10.1080/14767058.2017.1408068>
154. Amreen S, Suneel A, Shetty A, Vasudeva A, Kumar P Use of glycosylated HbA1c and random blood sugar as a screening tool for gestational diabetes mellitus in first trimester. *Int J Reprod Contracept Obstet Gynecol*, 2018;7: 524-8. DOI <https://doi.org/10.18203/2320-1770.ijrcog20180166>

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)